Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Germany's Merck expects drug division to drive growth-Euro am Sonntag

Published 23/05/2015, 12:15
© Reuters.  Germany's Merck expects drug division to drive growth-Euro am Sonntag
MRCG
-
SIAL
-
PFE
-

FRANKFURT (Reuters) - Germany's Merck KGaA (DE:MRCG) expects sales to grow by around 5 percent in its core operations over coming years, helped by its pipeline of prospective new drugs, its chief executive was quoted saying by weekly Euro am Sonntag.

Merck, which makes drugs, chemicals and laboratory supplies, posted group sales of 11.3 billion euros ($12.5 billion) in 2014, up 5.5 percent from the previous year.

After the $17 billion acquisition of Sigma-Aldrich Corp (O:SIAL), expected to be wrapped up around mid-year, the group aims to focus on organic or self-generated growth, CEO Karl-Ludwig Kley told the paper, adding he expects the drug pipeline to become the group's main driver.

Kley said that after years of setbacks in drug development, the division was now on track thanks to restructuring, expanding into the United States and biotechnology and thanks to a cancer drug deal with Pfizer (N:PFE).

Merck struck the alliance over cancer immunotherapy drugs in November, triggering an upfront payment of $850 million by the U.S. drugmaker.

The two companies will develop Merck's so-called anti-PD-L1 agent as a single therapy as well as in combinations with Pfizer's and Merck's portfolio of approved and experimental drug candidates.

Merck said earlier this week it sees adjusted core earnings (EBITDA) of between 3.45 billion euros ($3.9 billion) and 3.55 billion for 2015, implying an increase of between 1.8 and 4.8 percent, before including Sigma-Aldrich.

($1 = 0.9079 euros)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.